NewAmsterdam Pharma Sees Unusually High Options Volume (NASDAQ:NAMS)

NewAmsterdam Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Call-option trading surged: Investors bought 7,505 NAMS call options, about 962% above the typical volume of 707.
  • Shares traded at $19.39, near their one-year low of $17.90. Quarterly results beat estimates, with a loss of $0.14 per share versus a forecast loss of $0.47 and revenue of $19.16 million versus $8.82 million expected.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $49.82; ratings range from Strong Buy to Sell.
  • Five stocks to consider instead of NewAmsterdam Pharma.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders purchased 7,505 call options on the company. This is an increase of 962% compared to the typical volume of 707 call options.

NewAmsterdam Pharma Price Performance

NAMS traded down $0.07 during mid-day trading on Tuesday, hitting $19.39. The stock had a trading volume of 1,364,098 shares, compared to its average volume of 1,207,235. The stock's fifty day simple moving average is $21.41 and its 200-day simple moving average is $29.12. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -11.47 and a beta of 0.15. NewAmsterdam Pharma has a 1-year low of $17.90 and a 1-year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.33. NewAmsterdam Pharma had a negative net margin of 789.95% and a negative return on equity of 31.39%. The company had revenue of $19.16 million during the quarter, compared to analyst estimates of $8.82 million. As a group, research analysts expect that NewAmsterdam Pharma will post -1.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on NAMS shares. Jefferies Financial Group restated a "buy" rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an "outperform" rating and a $58.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Thursday, October 15th. Cantor Fitzgerald raised their target price on NewAmsterdam Pharma from $52.00 to $61.00 and gave the stock an "overweight" rating in a report on Wednesday, November 11th. Finally, Needham & Company LLC decreased their target price on NewAmsterdam Pharma from $48.00 to $46.00 and set a "buy" rating for the company in a research report on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $49.82.

View Our Latest Stock Analysis on NewAmsterdam Pharma

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director John W. Smither sold 1,600 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the sale, the director owned 8,760 shares of the company's stock, valued at $221,803.20. This represents a 15.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Davidson acquired 10,000 shares of the stock in a transaction on Monday, September 14th. The stock was bought at an average price of $22.65 per share, with a total value of $226,500.00. Following the transaction, the chief executive officer directly owned 792,923 shares in the company, valued at approximately $17,959,705.95. This represents a 1.28% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 176,846 shares of company stock valued at $4,661,919 over the last ninety days. 12.74% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP increased its holdings in shares of NewAmsterdam Pharma by 340.1% in the third quarter. Quarry LP now owns 20,000 shares of the company's stock worth $486,000 after acquiring an additional 15,456 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of NewAmsterdam Pharma by 27.1% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,984,732 shares of the company's stock valued at $48,269,000 after purchasing an additional 422,821 shares in the last quarter. Jump Financial LLC lifted its holdings in shares of NewAmsterdam Pharma by 147.4% during the 3rd quarter. Jump Financial LLC now owns 357,521 shares of the company's stock valued at $8,695,000 after purchasing an additional 213,009 shares in the last quarter. HighVista Strategies LLC lifted its holdings in shares of NewAmsterdam Pharma by 55.0% during the 3rd quarter. HighVista Strategies LLC now owns 32,410 shares of the company's stock valued at $788,000 after purchasing an additional 11,505 shares in the last quarter. Finally, Summit Wealth Group LLC acquired a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at approximately $730,000. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

(Get Free Report)

NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company's lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in NewAmsterdam Pharma Right Now?

Before you consider NewAmsterdam Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.

While NewAmsterdam Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines